High-risk human papilloma virus (HPV) and survival in patients with esophageal carcinoma: a pilot study

BMC Cancer

Table 1 Demographic description of patients for all investigated parameters. The distribution of HPV 16 positivity and median viral load is shown for all clinical subgroups. Tumor stage and performance status according to ECOG were correlated to patients survival in the univariate survival analysis, p-value is shown for all parameters. *Treatment management not included in survival analysis.

	Number of patients	Median survival in days	Univariate survival analysis p-value for each parameter	HPV 16 pos	HPV 16 viral load median value based on positive samples (genomes/human genome equivalents)
Gender			0.55
Male	71	292		10	2.7
Female	29	338		6	10.5
Age			0.84
65	39	292		7	2.1
65 +	61	307		9	6.6
Tumour stage			0.00055
Advanced disease	30	212		5	2.12
Localised disease	70	376		11	5.3
Histology			0.39
Squamous cell carcinoma	71	250		10	16.4
Adenocarcinoma	27	374		5	0.6
Mucoepidermoid	2	528		1	5.3
Tumor differentiation			0.46
Low differentiated	29	362		4	1.4
Middle	23	234		4	1.9
High	2	187		0	-
Not determined	46
Localisation of tumor			0.17
Upper	11	292		3	15.7
Middle	33	338		6	16.9
Lower	47	235		3	0.16
Not determined	9
Performance status			<0.0001
0	43	419		6	2.7
1	43	235		4	16.3
2	8	120		2	60.6
3	4	49		3	0.6
Not determined	2
Weight			0.12
Weight loss	82	236		10	0.6
No weight loss	18	414		6	6.0
Smoking habits			0.45
Non smoker	16	309		1	5.3
Smoker	45	292		4	8.7
Ex-smokers	22	235		6	2.7
Not determined	17
Alcohol usage			0.81
Alcohol use	50	339		6	5
No alcoholic use	6	450		1	5
Not determined	44
Treatment			*
Surgery+ Chemo-radiation	13	493		1	0.5
Curativ intended Chemo-radiation	24	445		5	5,3
Palliative chemotherapy and radiotherapy	47	234		5	15,7
Palliative chemotherapy	16	125		5	0.6

ISSN: 1471-2407